Abstract:Spatiotemporally controlled SRN‐T cells achieved a 1st release of Indoleamine 2,3‐dioxygenase inhibitors (IDOi) in an acidic tumor microenvironment (TME). The released IDOi restored tryptophan supply in TME, which activated effector T cells and inhibited Tregs. Meanwhile, 1st released core is internalized by tumor cells and degraded by glutathione (GSH), to realize a 2nd release of Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i), which induces up‐regulated expression of C‐X‐C motif chemokine ligand 10 (CXCL10) and C‐C motif chemokine ligand 5 (CCL5), and thus a significantly increased tumor infiltration of T cells. Together, with an enhanced recruitment and activation, T cells significantly suppress tumor growth. Due to multidimensional complexity of solid tumor, development of rational T‐cell combinations and corresponding formulations is still challenging. Herein, a triple combination of T cells are developed with Indoleamine 2,3‐dioxygenase inhibitors (IDOi) and Cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i). To maximize synergism, a spatiotemporally controlled T‐cell engineering technology to formulate triple drugs into one cell therapeutic, is established. Specifically, a sequentially responsive core‐shell nanoparticle (SRN) encapsulating IDOi and CDK4/6i is anchored onto T cells. The yielded SRN‐T cells migrated into solid tumor, and achieved a 1st release of IDOi in acidic tumor microenvironment (TME). Released IDOi restored tryptophan supply in TME, which activated effector T cells and inhibited Tregs. Meanwhile, 1st released core is internalized by tumor cells and degraded by glutathione (GSH), to realize a 2nd release of CDK4/6i, which induced up‐regulated expression of C‐X‐C motif chemokine ligand 10 (CXCL10) and C‐C motif chemokine ligand 5 (CCL5), and thus significantly increased tumor infiltration of T cells. Together, with an enhanced recruitment and activation, T cells significantly suppressed tumor growth, and prolonged survival of tumor‐bearing mice. This study demonstrated rationality and superiority of a tri‐drug combination mediated by spatiotemporally controlled cell‐engineering technology, which provides a new treatment regimen for solid tumor.

Spatiotemporally Controlled T‐Cell Combination Therapy for Solid Tumor

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Programing Immunogenic Cell Death in Breast Tumors with Designer DNA Frameworks

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

Tumor-targeting and Activatable Biomimetic Nanococktails Synergistically Regulate Immune Responses for Spatiotemporal Immunotherapy of Low Immunogenic Solid Tumors

Artificial “Nano-Targeted Cells” for Bimodal Imaging-Guided Tumor Cocktail Therapy

Triple-Combination Immunogenic Nanovesicles Reshape the Tumor Microenvironment to Potentiate Chemo-Immunotherapy in Preclinical Cancer Models

Activatable Biomimetic Raspberry-Like Nanoplatform Enabled Robust Cascade Therapy Via Spatiotemporal Regulation of Tumor Immunogenicity and Immunosuppression

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapy

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Modulating the Tumor Microenvironment Via Oncolytic Viruses and CSF-1R Inhibition Synergistically Enhances Anti-PD-1 Immunotherapy.

Spatiotemporal‐Controlled NIR‐II Immune Agonist Sensitizes Cancer Immunotherapy

Synergizing CXCL9 with BRD4‐PROTAC Using Nanochaperone Boosts Robust T Cell‐Dependent Antitumor Immune Responses for Cancer Immunotherapy

A T cell receptor β chain–directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity

Developing Oxaliplatin and IL-15 Co-carried Gels as Drug Depots to Enable Triple-Interlocked Combination Therapy for Colorectal Cancer

Gene-activating Nanomedicine for the Tumor-Oriented Infiltration of T Cells to Enhance Immunotherapy Against Solid Tumors

Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‐1 antibody suppresses the progression of non‐small cell lung cancer tumors by enhancing immunocompetence

Tumor-Microenvironment-Activatable Nanoparticle Mediating Immunogene Therapy and M2 Macrophage-Targeted Inhibitor for Synergistic Cancer Immunotherapy.